Steven E Hyman

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States

Are you Steven E Hyman?

Claim your profile

Publications (143)1523 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The World Health Organization is in the process of preparing the eleventh revision of the International Classification of Diseases (ICD-11), scheduled for presentation to the World Health Assembly for approval in 2017. The International Advisory Group for the Revision of the ICD-10 Mental and Behavioural Disorders made improvement in clinical utility an organizing priority for the revision. The uneven nature of the diagnostic information included in the ICD-10 Clinical Descriptions and Diagnostic Guidelines (CDDG), especially with respect to differential diagnosis, is a major shortcoming in terms of its usefulness to clinicians. Consequently, ICD-11 Working Groups were asked to collate diagnostic information about the disorders under their purview using a standardized template (referred to as a "Content Form"). Using the information provided in the Content Forms as source material, the ICD-11 CDDG are being developed with a uniform structure. The effectiveness of this format in producing more consistent clinical judgments in ICD-11 as compared to ICD-10 is currently being tested in a series of Internet-based field studies using standardized case material, and will also be tested in clinical settings. © 2015 World Psychiatric Association.
    World psychiatry: official journal of the World Psychiatric Association (WPA) 02/2015; 14(1):82-90. DOI:10.1002/wps.20189
  • Foreign affairs (Council on Foreign Relations) 01/2015; 94(1):127-135.
  • Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: Mental disorders have high aggregate prevalence, are responsible globally for nearly a quarter of all years lived with disability, and represent the largest cause of lost economic output among all classes of noncommunicable disease worldwide. Cost-effective treatments, including both generic drugs and brief, manualized cognitive therapies are available to address this burden. Nonetheless, treatment of mental disorders remains a low priority worldwide-disproportionately so in low- and middle-income countries. Here, I focus on possible reasons for the failure of policy-makers to respond effectively, and I suggest corrective approaches.
    Science translational medicine 09/2014; 6(253):253cm9. DOI:10.1126/scitranslmed.3010312
  • Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: In the face of growing controversy about the utility of genetic mouse models of human disease, Rothwell et al. report on a shared mechanism by which two different neuroligin-3 mutations, associated with autism spectrum disorders in humans, produce an enhancement in motor learning. The open question is how much we can learn about human ills from such models.
    Cell 07/2014; 158(1):13-4. DOI:10.1016/j.cell.2014.06.032
  • Steven E. Hyman
    AJOB Neuroscience 06/2014; 5(3). DOI:10.1080/21507740.2014.923668
  • Steven A McCarroll, Guoping Feng, Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: Genetic analysis is currently offering glimpses into molecular mechanisms underlying such neuropsychiatric disorders as schizophrenia, bipolar disorder and autism. After years of frustration, success in identifying disease-associated DNA sequence variation has followed from new genomic technologies, new genome data resources, and global collaborations that could achieve the scale necessary to find the genes underlying highly polygenic disorders. Here we describe early results from genome-scale studies of large numbers of subjects and the emerging significance of these results for neurobiology.
    Nature Neuroscience 06/2014; 17(6):756-63. DOI:10.1038/nn.3716
  • Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: The more we study the genetics of schizophrenia, says Steven E. Hyman, the more daunting -- and exciting -- are the challenges we see ahead.
    Nature 04/2014; 508(7494):S20. DOI:10.1038/508S20a
  • Steven E Hyman
    Nature medicine 02/2014; 20(2):118-9. DOI:10.1038/nm.3463
  • Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite high prevalence and enormous unmet medical need, the pharmaceutical industry has recently de-emphasized neuropsychiatric disorders as 'too difficult' a challenge to warrant major investment. Here I describe major obstacles to drug discovery and development including a lack of new molecular targets, shortcomings of current animal models, and the lack of biomarkers for clinical trials. My major focus, however, is on new technologies and scientific approaches to neuropsychiatric disorders that give promise for revitalizing therapeutics and may thus answer industry's concerns.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 01/2014; 39(1):220-9. DOI:10.1038/npp.2013.181
  • Steven A McCarroll, Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: Advances in genome analysis, accompanied by the assembly of large patient cohorts, are making possible successful genetic analyses of polygenic brain disorders. If the resulting molecular clues, previously hidden in the genomes of affected individuals, are to yield useful information about pathogenesis and inform the discovery of new treatments, neurobiology will have to rise to many difficult challenges. Here we review the underlying logic of the genetic investigations, describe in more detail progress in schizophrenia and autism, and outline the challenges for neurobiology that lie ahead. We argue that technologies at the disposal of neuroscience are adequately advanced to begin to study the biology of common and devastating polygenic disorders.
    Neuron 10/2013; 80(3):578-87. DOI:10.1016/j.neuron.2013.10.046
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroscience studies into psychiatric disorders generally rely on disease definitions that are based on the influential Diagnostic and Statistical Manual of Mental Disorders (DSM), the fifth edition of which (DSM-5) was released earlier this year. Designed as a purely diagnostic tool, the DSM considers different disorders as distinct entities. However, boundaries between disorders are often not as strict as the DSM suggests. To provide an alternative framework for research into psychiatric disorders, the US National Institute of Mental Health (NIMH) has recently introduced its Research Domain Criteria (RDoC) project. In the RDoC, five 'domains' each reflect a brain system in which functioning is impaired, to different degrees, in different psychiatric conditions. Nature Reviews Neuroscience asked six leading investigators for their thoughts on how DSM-5 and the RDoC will influence neuroscience research into psychiatric disorders.
    Nature Reviews Neuroscience 10/2013; 14(11):810-4. DOI:10.1038/nrn3621
  • Source
    Steven E Hyman
    Cerebrum: the Dana forum on brain science 01/2013; 2013:5.
  • Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug discovery is at a near standstill for treating psychiatric disorders such as schizophrenia, bipolar disorder, depression, and common forms of autism. Despite high prevalence and unmet medical need, major pharmaceutical companies are deemphasizing or exiting psychiatry, thus removing significant capacity from efforts to discover new medicines. In this Commentary, I develop a view of what has gone wrong scientifically and ask what can be done to address this parlous situation.
    Science translational medicine 10/2012; 4(155):155cm11. DOI:10.1126/scitranslmed.3003142
  • Steven E. Hyman, Eric J. Nestler
  • Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: A report in this issue suggests that inhibiting histone deacetylase 2 (HDAC2) could be therapeutic in schizophrenia. Targeting chromatin remodeling in adults to treat a chronic brain disorder is not, however, likely to be easy.
    Nature Neuroscience 08/2012; 15(9):1180-1. DOI:10.1038/nn.3200
  • Steven E. Hyman
    Trends in Cognitive Sciences 01/2012; 16(1):3-5. DOI:10.1016/j.tics.2011.10.007
  • Source
    Nature 07/2011; 475(7354):27-30. DOI:10.1038/475027a
  • Source
    Steven E Hyman
    Journal of Child Psychology and Psychiatry 03/2011; 52(6):661-2; discussion 673-5. DOI:10.1111/j.1469-7610.2011.02386.x
  • Source
    Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: Editor’s Note:If all goes as planned, the American Psychiatric Association will release a new Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in May 2013. Since 1980, the DSM has provided a shared diagnostic language to clinicians, patients, scientists, school systems, courts, and pharmaceutical and insurance companies; any changes to the influential manual will have serious ramifications. But, argues Dr. Steven Hyman, the DSM is a poor mirror of clinical and biological realities; a fundamentally new approach to diagnostic classification is needed as researchers uncover novel ways to study and understand mental illness.
    Cerebrum: the Dana forum on brain science 03/2011; 2011:6.
  • Source
    Steven E Hyman
    [Show abstract] [Hide abstract]
    ABSTRACT: The potential use of drugs to enhance cognition, emotion, and executive function has engendered controversy despite the fact that few such agents exist today. Here, I provide a context for discussions based on medical, regulatory, and ethical concerns that have been raised by the possibility that enhancers will emerge from current efforts to discover drugs for neuropsychiatric disorders.
    Neuron 02/2011; 69(4):595-8. DOI:10.1016/j.neuron.2011.02.012

Publication Stats

12k Citations
1,523.00 Total Impact Points

Institutions

  • 2012–2015
    • Broad Institute of MIT and Harvard
      • Stanley Center for Psychiatric Research
      Cambridge, Massachusetts, United States
    • Massachusetts Institute of Technology
      Cambridge, Massachusetts, United States
  • 1996–2014
    • National Institute of Mental Health (NIMH)
      • Laboratory of Systems Neuroscience
      베서스다, Maryland, United States
  • 1992–2013
    • Harvard University
      • Department of Chemistry and Chemical Biology
      Cambridge, Massachusetts, United States
    • Yale University
      • Department of Psychiatry
      New Haven, CT, United States
  • 2010
    • Icahn School of Medicine at Mount Sinai
      Manhattan, New York, United States
  • 1988–2009
    • Massachusetts General Hospital
      • • Department of Neurology
      • • Department of Radiology
      • • Department of Psychiatry
      • • Molecular Neurobiology Laboratory
      • • Molecular Biology Laboratory
      Boston, Massachusetts, United States
  • 1994–2007
    • Harvard Medical School
      • • Department of Neurobiology
      • • Department of Anesthesia
      Boston, MA, United States
  • 2000
    • Boston University
      • Department of Psychology
      Boston, Massachusetts, United States
  • 1997–2000
    • National Institutes of Health
      • Section on Molecular Regulation
      Maryland, United States
  • 1990
    • McLean Hospital
      • Molecular Pharmacology Laboratory
      Cambridge, MA, United States
  • 1987
    • Beverly Hospital, Boston MA
      BVY, Massachusetts, United States